Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

Impact · against what's priced in

Soleno Therapeutics faces catastrophic risks as a class action lawsuit formalizes allegations of heart failure safety signals and data integrity fraud. The company's admission of a disrupted launch trajectory confirms a significant loss of commercial momentum for its primary product, VYKAT™ XR.

SLNO−0.90

No priced-in read yet